An unusual presentation of inflammatory myopathy in a patient on natalizumab treatment for multiple sclerosis: A case report and review of myopathological classification of inflammatory myopathy
Journal Title: International Journal of Clinical Rheumatology - Year 2018, Vol 13, Issue 3
Abstract
Acquired immune and inflammatory myopathies (IIMs) are traditionally subdivided into dermatomyositis, polymyositis, inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM). Our patient is a 38-year old female who had history of Multiple Sclerosis and was on Natalizumab. Almost a year later, she presented with acute proximal bilateral upper extremity weakness with elevated CPK. She was initially labeled as having ‘viral myositis’. Her subsequent two admissions demonstrated worsening of muscle weakness with dysphagia which was initially unresponsive to high dose of steroids. She had an EMG which showed irritative myopathy and a muscle biopsy which showed IMPP. She eventually responded to pulse dose of steroids and IVIG and Natalizumab was held. The temporal relationship between the development of inflammatory myopathy in our patient and subsequent improvement in her course after discontinuation of the drug suggests that natalizumab may have played a role in our patient’s disease and warrants further investigation and vigilance. In addition to the case report, we hope to elaborate on the myopathological descriptions increasingly being used to describe the IIMs and to explore the potential link between natalizumab and the onset of IIM in our patient.
Authors and Affiliations
Beenish Zulfiqar, Jacquelin Chua, Stacy Weinberg, Sobia Hassan
Keywords
Related Articles
- EP ID EP604508
- DOI -
- Views 63
- Downloads 0
A rare complex mutation in FMF gene; genetics and treatment decisions in Familial Mediterranean Fever patients
Introduction: FMF is an autosomal-recessive autoinflammatory disease characterized by episodic, self-limiting attacks characterized by fever, abdominal pain, pleurisy, arthritis and erysipelas-like-erythema. Systemic amy...
HLA class I and II alleles may influence susceptibility to adult dermatomyositis in a Mexican mestizo population
Objective: To investigate the possible association between HLA and Dermatomyositis (DM) in the Mexican mestizo population. Methods: HLA class I (A and B) and class II (DRB1* and DQB1*) were determined in 36 Mexican mest...
Adalimumab induced chronic interstitial nephritis: a controlled blinded trial in mice
Background: Adalimumab is a known drug modifying agent for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) treatment. However little is known about the risk of nephrotoxicity. To determine whether the i...
Refractory thrombocytopenia in SLE patient with massive thigh hematoma and hematuria successfully treated with Rituximab: Case Report
Background: Systemic Lupus Erythematosus is a multisystemic inflammatory disease with broad clinical presentation, 9.5% to 44.5% of patients with SLE have thrombocytopenia complication of different grades. No significant...
An unusual presentation of inflammatory myopathy in a patient on natalizumab treatment for multiple sclerosis: A case report and review of myopathological classification of inflammatory myopathy
Acquired immune and inflammatory myopathies (IIMs) are traditionally subdivided into dermatomyositis, polymyositis, inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM). Our patient is a 38-year old fe...